[The relationship between inflammatory mediators and pulmonary hypertension in patients with chronic obstructive pulmonary disease]
- PMID: 22333502
[The relationship between inflammatory mediators and pulmonary hypertension in patients with chronic obstructive pulmonary disease]
Abstract
Objective: The levels of C-reactive protein (CRP), tumor necrosis factor (TNF)-α, brain natriuretic peptide (BNP) and endothelin-1 (ET-1) were investigated to analyze the systemic inflammation in chronic obstructive pulmonary disease (COPD) patients with and without pulmonary hypertension.
Methods: From January 2006 to December 2010, 89 patients with COPD were enrolled in our hospital. There were 67 males and 22 females, with a mean age of (70 ± 7) and a mean FEV(1) of (47 ± 13)%. Pulmonary pressure was assessed by Doppler echocardiography. The levels of plasma BNP, TNF-α and ET-1 were measured by enzyme-linked immunosorbent assay kits. High-sensitivity plasma CRP level was assessed by chemiluminescent immunoassay.
Results: Forty-two patients were classified as COPD with pulmonary hypertension group and 47 patients as COPD without pulmonary hypertension group. The level of CRP [51.4 mg/L (20.1 - 92.0) mg/L], ET-1 [5.9 ng/L (3.7 - 10.4) ng/L] and BNP [303.2 ng/L (112.5 - 824.7) ng/L] in patients with pulmonary hypertension were significantly higher than in that in patients without hypertension, CRP [26.7 mg/L (11.5 - 62.9) mg/L], ET-1 [2.1 ng/L (1.3 - 4.7) ng/L] and BNP [143.7 ng/L (85.5 - 306.7) ng/L]. The level of TNF-α showed no difference between the 2 groups [8.5 ng/L (4.8 - 13.7) ng/L and 6.7 ng/L (3.2 - 10.3) ng/L], respectively. Multivariate analysis showed that PaO₂ (P < 0.05), CRP (P < 0.05) and BNP (P < 0.05) could predict pulmonary hypertension independently.
Conclusion: The level of CRP, ET-1 and BNP were related to pulmonary hypertension in COPD patients, suggesting that systemic inflammation play a role in the pathogenesis of pulmonary hypertension in COPD.
Similar articles
-
Systemic inflammation in patients with COPD and pulmonary hypertension.Chest. 2006 Aug;130(2):326-33. doi: 10.1378/chest.130.2.326. Chest. 2006. PMID: 16899829
-
The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease.Eur J Intern Med. 2008 Mar;19(2):104-8. doi: 10.1016/j.ejim.2007.04.026. Eur J Intern Med. 2008. PMID: 18249305
-
Circulating visfatin in chronic obstructive pulmonary disease.Nutrition. 2009 Apr;25(4):373-8. doi: 10.1016/j.nut.2008.09.008. Epub 2008 Dec 4. Nutrition. 2009. PMID: 19056239
-
Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease.Ann Med. 2013 May;45(3):291-300. doi: 10.3109/07853890.2012.732703. Epub 2012 Oct 30. Ann Med. 2013. PMID: 23110517 Review.
-
Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection?Proc Am Thorac Soc. 2009 Dec;6(8):638-47. doi: 10.1513/pats.200907-073DP. Proc Am Thorac Soc. 2009. PMID: 20008867 Review.
Cited by
-
iTRAQ-Based Proteomics Reveals Novel Biomarkers for Idiopathic Pulmonary Fibrosis.PLoS One. 2017 Jan 25;12(1):e0170741. doi: 10.1371/journal.pone.0170741. eCollection 2017. PLoS One. 2017. PMID: 28122020 Free PMC article.
-
Inflammatory markers are elevated in Eisenmenger syndrome.Pediatr Cardiol. 2013;34(8):1791-6. doi: 10.1007/s00246-013-0715-3. Epub 2013 May 11. Pediatr Cardiol. 2013. PMID: 23666048
-
Clinical Value of FeNO for Pulmonary Hypertension Diagnosis in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Emerg Med Int. 2022 Jan 28;2022:9924047. doi: 10.1155/2022/9924047. eCollection 2022. Emerg Med Int. 2022. PMID: 35127179 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous